Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies

Inclusion criteria

• ✓. Age 18 - 70 years old, gender not restricted;
• ✓. Patients with untreated primary advanced biliary system malignancies diagnosed by pathological histology or cytology;
• ✓. Physical condition: ECOG PS score 0 - 1;
• ✓. Pathological laboratory assessment: EGFR IHC ≥ 1+;
• ✓. Have undergone at least one line of systemic drug treatment;
• ✓. According to the RECIST 1.1 standard, at least one measurable target lesion that can be detected by CT or MRI;
• ✓. Laboratory test indicators meet the following requirements:
• ✓. Pregnant women agree to use contraception during the study period and within 6 months after the study ends; The serum or urine pregnancy test is negative within 7 days before the study entry, and non-lactating patients; Male patients agree to use contraception during the study period and within 6 months after the study ends;